Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590642 · ClinicalTrials.gov registry record
Augmentation in Tx-resistant OCD: an Open Label Trial
A clinical trial, sponsored by Creighton University.
- Completed
- Registry status
- 30
- Enrollment target
NCT00590642: Completed study, sponsored by Creighton University.
NCT00590642 is a clinical trial that has completed, run by Creighton University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590642 has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study examines the use of Acamprosate (Campral(R)) in the treatment of Obsessive Compulsive Disorder (OCD). The treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. Such patients are referred to as having treatment resistant OCD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-10 |
What the finished NCT00590642 record still lists
NCT00590642 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00590642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00590642 about?
NCT00590642 is a clinical study titled "Augmentation in Tx-resistant OCD: an Open Label Trial". This study examines the use of Acamprosate (Campral(R)) in the treatment of Obsessive Compulsive Disorder (OCD). The treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. Such patients are referred to as having treatme...
What is the current status of trial NCT00590642?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2009-10.
Who is sponsoring clinical trial NCT00590642?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia